Skip to main content


Managing Clinical and Psychosocial Impacts of OFS
Hear expert commentary on ovarian function suppression (OFS) side effect management, including strategies used to address psychosocial challenges affecting premenopausal breast cancer patients undergoing OFS. Read More ›

Fertility Preservation and Benefits of OFS
Polly Niravath, MD, discusses fertility preservation in premenopausal women with breast cancer who are undergoing ovarian function suppression (OFS) treatment. Read More ›

Setting Patient Expectations of OFS Treatment
Listen as a nurse navigator discusses ovarian function suppression (OFS) and the subsequent impact of OFS on premenopausal women with breast cancer. Read More ›

Thinking outside the box: Strategies to combat staff shortages
Hear strategies for how community-based oncology practices can combat the pervasive staff shortage by increasing efficiency and reducing staff burnout. Read More ›

Real-world Outcomes Following Initiation of Abemaciclib in Patients With Brain Metastases Secondary to HR+/HER2- Metastatic Breast Cancer
Dr Rugo of the University of California San Francisco Comprehensive Cancer Center reports on the outcomes of a retrospective study of patients with metastatic breast cancer and brain metastases treated with abemaciclib. Read More ›

Primary Analysis of HER2CLIMB-02: Addition of Tucatinib to Trastuzumab Emtansine in Previously Treated Patients with HER2-Positive Metastatic Breast Cancer
Dr Tolaney of Dana-Farber Cancer Institute reviews data on HER2CLIMB-02 and contributes future considerations of tucatinib in the metastatic HER2-positive breast cancer setting. Read More ›

INAVO120 Phase III Study: Treatment of Patients With PIK3CA-mutant, HR+/HER2- Locally Advanced or Metastatic Breast Cancer With Invavolisib in Combination With Palbociclib and Fulvestrant
Dr Rugo of the University of California San Francisco Comprehensive Cancer Center provides her insights on the practical aspects of the reported results of the INAVO120 phase 3 study. Read More ›

Abemaciclib and NSAI for 1L Treatment of HR+/HER2- Advanced Breast Cancer: Long-term Survival Data Reported
Dr Tolaney of Dana-Farber Cancer Institute discusses her perspectives on the clinically meaningful overall survival outcomes of abemaciclib added to a nonsteroidal aromatase inhibitor as initial therapy in patients with HR+/HER2- advanced breast cancer. Read More ›

Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer
This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study. Read More ›

New Developments on Prognostic Markers for Patients With Early Breast Cancer
This second installment discusses data presented at ESMO 2023 on prognostic markers for patients with early breast cancer, highlighting data from the monarchE study, the NATALEE study, and the BCIRG 001 and 005 trials. Read More ›

Page 1 of 16